Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8673MR)

This product GTTS-WQ8673MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8673MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2477MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ9729MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ7137MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ6756MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ6637MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ1936MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ8142MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ10252MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW